title: Pre- and post-operative adjuvant chemotherapy in colorectal cancer.
abstract: A multi-center randomized controlled study was conducted in order to investigate the usefulness of pre- and post-operative adjuvant chemotherapy in colorectal cancer. The patients were stratified into those with colon cancer and those with rectal cancer and divided into 2 groups, Group A and Group B. The patients in Group A received tegafur suppositories (750 mg/day) from 1 to 2 weeks prior to surgery, to 2 weeks following surgery and then oral administration of tegafur and uracil (UFT) (260 mg/m(2)) for 1 year. The patients in Group B, on the other hand, received only UFT (260 mg/m(2)) for 1 year beginning week 2 after surgery. Although there was no significant difference between Groups A and B in the 5-year survival rate, the 5-year disease-free survival rate was significantly higher in Group A, especially for rectal cancer (p<0.05). In addition, remote metastases tended to be suppressed for both colon and rectal cancer in Group A (p=0.08 and p=0.072). There was no serious adverse reaction to tegafur. Pre- and post-operative adjuvant chemotherapy with tegafur had fewer adverse reactions and was convenient to administer. Thus, it was considered useful for suppression of postoperative distant metastasis in colorectal cancer.
authors.affiliation: Department of Surgery, Kurume University Medical Center, Fukuoka 839-0863, Japan. isomoto@med.kurume-u.ac.jp
authors.forename: Hiroharu
authors.initials: H
authors.lastname: Isomoto
authors.forename: Masao
authors.initials: M
authors.lastname: Tomita
authors.forename: Keizo
authors.initials: K
authors.lastname: Sugimachi
authors.forename: Michio
authors.initials: M
authors.lastname: Ogawa
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Yamada
authors.forename: Tohru
authors.initials: T
authors.lastname: Nakagoe
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Sadamu
authors.initials: S
authors.lastname: Takano
authors.forename: Teruo
authors.initials: T
authors.lastname: Kakegawa
mesh_terms: D000368:Aged; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D012008:Recurrence; D005641:Tegafur / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors; D014498:Uracil / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil